Please provide your email address to receive an email when new articles are posted on . Pembrolizumab added to twice weekly gemcitabine plus transurethral muscle-invasive urothelial cancer resection ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) ...
The FDA approves a new diagnostic tool enhancing precision treatment for advanced endometrial carcinoma, improving patient ...
During a live event, Moshe C. Ornstein, MD, MA, considered the trial design and outcomes of 2 trials of combination regimens ...
Starting immunotherapy prior to surgical resection led to better outcomes vs standard, adjuvant-only immunotherapy in a phase 2 trial of patients with advanced melanoma. Treatment with neoadjuvant and ...
A combination of belzutifan, pembrolizumab, and lenvatinib showed encouraging results as first-line treatment for advanced RCC in an early phase trial. Phase 3 trial data are pending. Among first-line ...
While immune checkpoint inhibitors (anti-PD-1 +/- anti-CTLA-4) are approved as first line treatment for microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC), many patients ...
Merck's Keytruda wins EU approval for a new injectable form, offering greater treatment options for adults. Read more here.
New NSCLC guideline updates outline expanded perioperative immunotherapy, adjuvant targeted therapy, and consolidation ...
The US Food and Drug Administration (FDA) has approved the checkpoint inhibitor pembrolizumab (Keytruda, Merck) alongside standard chemotherapy — with or without bevacizumab — as first-line therapy ...
Barbara Burtness, MD highlights key news in head and neck cancer from ESMO 2025, including CAMORAL, ASPEN-03 & -04, OrigAMI-4 & -05 results.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback